{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:53:51Z","timestamp":1790409231914,"version":"4.1.0"},"reference-count":43,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"unspecified","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C7852\/A25447"],"award-info":[{"award-number":["C7852\/A25447"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C9203\/A24078"],"award-info":[{"award-number":["C9203\/A24078"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,10,5]]},"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Multiple myeloma is a plasma cell malignancy that accounts for 1%\u20132% of newly diagnosed cancers.<\/jats:p>\n                    <jats:p>At diagnosis, approximately 20% of patients can be identified, using cytogenetics, to have inferior survival (high-risk). Additionally, standard-risk patients, with detectable disease (minimal residual disease (MRD)-positive) postautologus stem cell transplant (ASCT), fare worse compared with those who do not (MRD-negative). Research is required to determine whether a risk-adapted approach post-ASCT could further improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>RADAR is a UK, multicentre, risk-adapted, response-guided, open-label, randomised controlled trial for transplant-eligible newly diagnosed multiple myeloma patients, using combinations of lenalidomide (R), cyclophosphamide (Cy), bortezomib (Bor), dexamethasone (D) and isatuximab (Isa).<\/jats:p>\n                    <jats:p>Participants receive RCyBorD(x4) induction therapy, followed by high-dose melphalan and ASCT. Post-ASCT, there are three pathways as follows:<\/jats:p>\n                    <jats:list list-type=\"order\">\n                      <jats:list-item>\n                        <jats:p>A phase III discontinuation design to assess de-escalating therapy in standard-risk MRD-negative patients. Participants receive 12 cycles of Isa maintenance. Those who remain MRD-negative are randomised to either continue or stop treatment.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>A phase II\/III multiarm multistage design to test treatment strategies for treatment escalation in standard-risk MRD-positive patients. Participants are randomised to either; R, RBorD(x4) +R, RIsa, or RBorIsaD(x4) + RIsa.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>A phase II design to assess the activity of intensive treatment strategies in high-risk patients. Participants are randomised to RBorD(x4) +R or RBorIsaD(x4) + RIsa.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                    <jats:p>1400 participants will be registered to allow for 500, 450 and 172 participants in each pathway. Randomisations are equal and treatment is given until disease progression or intolerance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval was granted by the London\u2013Central Research Ethics Committee (20\/LO\/0238) and capacity and capability confirmed by the appropriate local research and development department for each participating centre prior to opening recruitment. Participant informed consent is required before trial registration and reconfirmed post-ASCT. Results will be disseminated by conference presentations and peer-reviewed publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ISCRTN46841867.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-063037","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T09:31:06Z","timestamp":1668677466000},"page":"e063037","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II\/III randomised controlled trial"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0225-1199","authenticated-orcid":false,"given":"Kara-Louise","family":"Royle","sequence":"first","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1810-409X","authenticated-orcid":false,"given":"Amy Beth","family":"Coulson","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Ramasamy","sequence":"additional","affiliation":[{"name":"Radcliffe Department of Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Cairns","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hockaday","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Quezada","sequence":"additional","affiliation":[{"name":"Department of Haematology, UCL Cancer Institute, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Drayson","sequence":"additional","affiliation":[{"name":"Clinical Immunology Service, Institute of Immunology and Immunotherapy, Medical School, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Centre for Myeloma Research, Division of Molecular Pathology, Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Owen","sequence":"additional","affiliation":[{"name":"HMDS, St James\u2019s University Hospital, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4040-0642","authenticated-orcid":false,"given":"Holger W","family":"Auner","sequence":"additional","affiliation":[{"name":"Department of Immunology and Inflammation, Imperial College London, London, UK"},{"name":"Langmuir Centre for Myeloma Research, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK"},{"name":"Leeds Cancer Centre, St James\u2019s University Hospital, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Meads","sequence":"additional","affiliation":[{"name":"Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Olivier","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Barnard","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhiannon","family":"Lambkin","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Paterson","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryony","family":"Dawkins","sequence":"additional","affiliation":[{"name":"Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Chapman","sequence":"additional","affiliation":[{"name":"Department of Haematology, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Pratt","sequence":"additional","affiliation":[{"name":"Department of Haematology, Queen Elizabeth Hospital, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Popat","sequence":"additional","affiliation":[{"name":"Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Jackson","sequence":"additional","affiliation":[{"name":"Northern Centre for Cancer Care, Freeman Hospital, Newcastle-Upon-Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceri","family":"Bygrave","sequence":"additional","affiliation":[{"name":"Department of Haematology, University Hospital of Wales, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Sive","sequence":"additional","affiliation":[{"name":"Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"de Tute","sequence":"additional","affiliation":[{"name":"HMDS, St James\u2019s University Hospital, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Chantry","sequence":"additional","affiliation":[{"name":"Department of Haematology, Royal Hallamshire Hospital, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Parrish","sequence":"additional","affiliation":[{"name":"Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Cook","sequence":"additional","affiliation":[{"name":"Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK"},{"name":"Bristol Myers Squibb, Boundry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Asher","sequence":"additional","affiliation":[{"name":"Department of Haematology, UCL Cancer Institute, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwee","family":"Yong","sequence":"additional","affiliation":[{"name":"Department of Haematology, UCL Cancer Institute, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,11,17]]},"reference":[{"key":"2025121605444842000_12.11.e063037.1","unstructured":"Cancer Research UK . Myeloma incidence statistics 2015, 2018. Available: http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/myeloma\/incidence [Accessed 21 Oct 2018]."},{"key":"2025121605444842000_12.11.e063037.2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.23"},{"key":"2025121605444842000_12.11.e063037.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022340"},{"key":"2025121605444842000_12.11.e063037.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204"},{"key":"2025121605444842000_12.11.e063037.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750"},{"key":"2025121605444842000_12.11.e063037.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070596"},{"key":"2025121605444842000_12.11.e063037.7","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025121605444842000_12.11.e063037.8","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.120121"},{"key":"2025121605444842000_12.11.e063037.9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-395749"},{"key":"2025121605444842000_12.11.e063037.10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"key":"2025121605444842000_12.11.e063037.11","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.clml.2017.02.018","article-title":"High-risk multiple myeloma: definition and management","volume":"17S","author":"Joseph","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025121605444842000_12.11.e063037.12","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.247"},{"key":"2025121605444842000_12.11.e063037.13","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/leu.2017.179","article-title":"Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients","volume":"32","author":"Shah","year":"2018","journal-title":"Leukemia"},{"key":"2025121605444842000_12.11.e063037.14","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.204"},{"key":"2025121605444842000_12.11.e063037.15","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.127"},{"key":"2025121605444842000_12.11.e063037.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"2025121605444842000_12.11.e063037.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-159624"},{"key":"2025121605444842000_12.11.e063037.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.2119"},{"key":"2025121605444842000_12.11.e063037.19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-568907"},{"key":"2025121605444842000_12.11.e063037.20","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0147-7","article-title":"Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma","volume":"8","author":"Sidiqi","year":"2018","journal-title":"Blood Cancer J"},{"key":"2025121605444842000_12.11.e063037.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"2025121605444842000_12.11.e063037.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32556-5"},{"key":"2025121605444842000_12.11.e063037.23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0695"},{"key":"2025121605444842000_12.11.e063037.24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"2025121605444842000_12.11.e063037.25","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025121605444842000_12.11.e063037.26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"key":"2025121605444842000_12.11.e063037.27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-791228"},{"key":"2025121605444842000_12.11.e063037.28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7586"},{"key":"2025121605444842000_12.11.e063037.29","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00930.x"},{"key":"2025121605444842000_12.11.e063037.30","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"2025121605444842000_12.11.e063037.31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"2025121605444842000_12.11.e063037.32","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1182\/blood.V128.22.1143.1143","article-title":"Lenalidomide is a highly effective maintenance therapy in myeloma patients of all ages; results of the phase III myeloma XI study","volume":"128","author":"Jackson","year":"2016","journal-title":"Blood"},{"key":"2025121605444842000_12.11.e063037.33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.0107"},{"key":"2025121605444842000_12.11.e063037.34","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/bjh.15459","article-title":"Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the medical Research Council myeloma IX randomised study","volume":"182","author":"Royle","year":"2018","journal-title":"Br J Haematol"},{"key":"2025121605444842000_12.11.e063037.35","first-page":"191","volume-title":"American Society of haematology (57th annual meeting and exposition","volume":"126","author":"Avet-Loiseau","year":"2015"},{"key":"2025121605444842000_12.11.e063037.36","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-13-139"},{"key":"2025121605444842000_12.11.e063037.37","first-page":"1375","article-title":"Randomized phase II clinical trials","volume":"69","author":"Simon","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"2025121605444842000_12.11.e063037.38","doi-asserted-by":"publisher","DOI":"10.1002\/sim.721"},{"key":"2025121605444842000_12.11.e063037.39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-271676"},{"key":"2025121605444842000_12.11.e063037.40","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12454577"},{"key":"2025121605444842000_12.11.e063037.41","unstructured":"NICE . Guide to the methods of technology appraisal 2013. London; 2013."},{"key":"2025121605444842000_12.11.e063037.42","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200205000-00009"},{"key":"2025121605444842000_12.11.e063037.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.01.004"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-063037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:44:58Z","timestamp":1765892698000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-063037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":43,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11,17]]},"published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1136\/bmjopen-2022-063037"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-063037","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}